Study S001611

Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02255266
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 1788
Start: 2015-03-26
Primary completion: 2015-11-16
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:liraglutide
Results posted: FALSE
Secondary identifiers: OTHER:U1111-1143-9842

Registered primary outcomes

Frequency of patients achieving HbA1c reduction of at least 1%-point [Week 0, week 52]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0021178	Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study. Lapolla A, Advances in therapy	2018	Randomized trial	PMID 29270781 DOI	cites ClinicalTrials.gov:NCT02255266; registry reference RESULT:29270781